Timothy J. Kulis

Senior Associate


Timothy (Tim) Kulis represents public and private companies at all stages of growth in corporate and securities law matters. He represents companies in mergers and acquisitions, public offerings and venture capital financings. In addition, he advises public company clients on ongoing corporate legal matters, including federal securities reporting requirements. Mr. Kulis represents clients in a range of industries, including technology, life sciences and defense.

Mr. Kulis was previously a summer associate in WilmerHale's Boston office, and at another Boston law firm. Prior to law school, he worked for US-based multinational e-commerce company Wayfair and served as a legislative aide intern in the office of Massachusetts Senator Robert L. Hedlund.

Recent Highlights

Capital Markets

  • Tetraphase Pharmaceuticals in its $65 million follow-on public offering of common stock
  • Blue Apron in its $300 million initial public offering of Class A common stock
  • Aileron Therapeutics in its $56.25 million initial public offering of common stock
  • Catabasis Pharmaceuticals in its $11.5 million follow-on public offering of common stock
  • MacroGenics' $150 million follow-on public offering of common stock (underwriters' counsel)
  • CoNCERT Pharmaceuticals in its $50 million follow-on public offering of common stock
  • Endurance International Group in its $262 million follow-on public offering of common stock

Mergers and Acquisitions

  • CIRCOR International in its acquisition of Colfax's fluid handling business for $855 million
  • American Science and Engineering in its acquisition by OSI Systems for $269 million
  • PAREXEL International in its acquisition of Health Advances
  • Thermo Fisher Scientific in its acquisition of Alfa Aesar research chemicals business of Johnson Matthey for $405 million

Venture Capital Transactions

  • Translate Bio in its Series C financing
  • Blue Apron in its $64.6 million convertible promissory note financing
  • Dataxu in its $20 million late-stage financing
  • Blue Apron in its $135 million Series D financing

Publications & News


September 28, 2017

WilmerHale Represents CIRCOR in $855M Acquisition of Colfax’s Fluid Handling Business from Colfax Corp.

CIRCOR International, Inc.—a leading provider of flow control solutions and other highly engineered products for markets including oil & gas, aerospace, power, process and general industrial—announced that it has signed a definitive agreement to acquire Colfax Fluid Handling (CFH) from Colfax Corporation for approximately $855 million including cash, newly issued CIRCOR shares, and the assumption of pension plan liabilities linked to the CFH business.

August 7, 2017

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

July 5, 2017

WilmerHale Represents Blue Apron Holdings, Inc. in IPO

Blue Apron's mission is to make incredible home cooking accessible to everyone. Launched in 2012, Blue Apron has grown to $795 million in annual revenue to become the leading US meal plan delivery company.

April 28, 2017

2017 IPO Report

Our 2017 IPO Report offers a detailed analysis of, and outlook for, the IPO market, plus useful IPO market metrics. We look at rates of adoption of JOBS Act relief by emerging growth companies, the potential impact of the new presidential administration on policy and direction at the US Securities and Exchange Commission and much more.

October 6, 2016

WilmerHale Advises Catabasis Pharmaceuticals in Closing of $11.5M Offering of Common Stock

The WilmerHale deal team was led by Partner Rosemary Reilly and included Counsel Jeffries Oliver-Li, Associate Timothy Kulis, and Attorney Heidi Treiber.

June 22, 2016

WilmerHale Reps AS&E in $269M Acquisition by OSI Systems

American Science and Engineering, Inc., a leading worldwide supplier of innovative X-ray inspection solutions, announced that it has entered into a definitive agreement to be acquired by OSI Systems, Inc. for a total transaction value of approximately $269 million.

June 29, 2015

WilmerHale Reps Thermo Fisher Scientific in Agreement to Acquire Alfa Aesar

On June 25, Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals.


Skip Navigation Links.


JD, cum laude, Boston College Law School, 2014, Senior Editor, Boston College Law Review

BA, Political Science, summa cum laude, Boston College, 2009

Bar Admissions


Skip Navigation Links.